180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases

PALO ALTO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) — 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has entered into a new, exclusive global licensing agreement [Read More]

INKplant project targets use of AM in regenerative medicine to address aging of European population

Originally posted on https://www.3dprintingmedia.network/inkplant-prints-the-future-of-regenerative-medicine-to-face-aging-of-the-european-population/ Population aging is one of Europe’s great challenges in the 21st century. By 2024, 22% of Europeans are expected to be over 65. Patients suffering from chronic joint detop fects or defects in the oral and maxillofacial regions have a significantly reduced quality of life and are continually dependent on health [Read More]

Regenerative Medicine: Industry Trends

Originally posted: https://www.pharmaceutical-technology.com/comment/regenerative-medicine-industry-trends/ Regenerative medicine is a multidisciplinary field that seeks to develop the science and tools that can help repair, augment, replace, or regenerate damaged or diseased human cells, tissues, genes, organs, or metabolic processes, to restore normal function. Regenerative medicine may involve the transplantation of stem cells, progenitor cells, or tissue, stimulation of [Read More]

Engineering Tissue-Informed Biomaterials to Advance Pulmonary Regenerative Medicine

This article was originally published here Front Med (Lausanne). 2021 Apr 8;8:647834. doi: 10.3389/fmed.2021.647834. eCollection 2021. Biomaterials intentionally designed to support the expansion, differentiation, and three-dimensional (3D) culture of induced-pluripotent stem cells (iPSCs) may pave the way to cell-based therapies for chronic respiratory diseases. These conditions are endured by millions of people worldwide and represent a [Read More]

Advancing the Development of Safe and Effective Regenerative Medicine Products

By: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research The U.S. Food and Drug Administration plays a vital role in facilitating the development and availability of innovative medical products. Products such as cellular-derived therapies, including stem cell-based products, offer the potential to treat or even cure diseases or conditions for which few [Read More]

FDA Crackdown on Stem Cell Quacks

Medicine is poised at an important junction. Moving forward, stem cell therapies could result in substantial innovation. Alternatively, unregulated clinicians in private practice could take this branch of medicine down the path of quackery. The FDA is ready to tighten regulations, leaving the stem cell community on tenterhooks. Patients hoping to benefit from increased access [Read More]

Get our newsletter for the latest news & updates.

Share the knowledge: